Role of Estrogen Receptor Signaling in Breast Cancer Metastasis

Metastatic breast cancer is a life-threatening stage of cancer and is the leading cause of death in advanced breast cancer patients. Estrogen signaling and the estrogen receptor (ER) are implicated in breast cancer progression, and the majority of the human breast cancers start out as estrogen dependent. Accumulating evidence suggests that ER signaling is complex, involving coregulatory proteins and extranuclear actions. ER-coregualtory proteins are tightly regulated under normal conditions with miss expression primarily reported in cancer. Deregulation of ER coregualtors or ER extranuclear signaling has potential to promote metastasis in ER-positive breast cancer cells. This review summarizes the emerging role of ER signaling in promoting metastasis of breast cancer cells, discusses the molecular mechanisms by which ER signaling contributes to metastasis, and explores possible therapeutic targets to block ER-driven metastasis.

[1]  R. Lanz,et al.  Nuclear receptor coregulators: cellular and molecular biology. , 1999, Endocrine reviews.

[2]  Ted M. Lakowski,et al.  Nη-substituted arginyl peptide inhibitors of protein arginine N-methyltransferases. , 2010, ACS chemical biology.

[3]  W. Sellers,et al.  High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. , 2004, Cancer cell.

[4]  Jorma Isola,et al.  Estrogen Receptor β Is Coexpressed with ERα and PR and Associated with Nodal Status, Grade, and Proliferation Rate in Breast Cancer , 2000 .

[5]  Diego Sisci,et al.  Fibronectin and type IV collagen activate ERα AF-1 by c-Src pathway: effect on breast cancer cell motility , 2004, Oncogene.

[6]  C. J. Barnes,et al.  Novel estrogen receptor coregulators and signaling molecules in human diseases , 2004, Cellular and Molecular Life Sciences CMLS.

[7]  J. Gustafsson,et al.  The estrogen receptor family. , 1999, Current opinion in obstetrics & gynecology.

[8]  B. O’Malley,et al.  Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation , 2009, Proceedings of the National Academy of Sciences.

[9]  V. Jordan,et al.  Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs). , 2005, Breast disease.

[10]  Andrea Riccardo Genazzani,et al.  Extra-Nuclear Signalling of Estrogen Receptor to Breast Cancer Cytoskeletal Remodelling, Migration and Invasion , 2008, PloS one.

[11]  Jianming Xu,et al.  The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis. , 2009, Cancer research.

[12]  S. Fuqua,et al.  Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. , 2011, Cancer research.

[13]  Toshiaki Utsumi,et al.  Recent perspectives of endocrine therapy for breast cancer , 2007, Breast cancer.

[14]  Cory C. Funk,et al.  Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. , 2006, Molecular endocrinology.

[15]  K. Korach,et al.  Estrogen receptor transcription and transactivation Estrogen receptor knockout mice: what their phenotypes reveal about mechanisms of estrogen action , 2000 .

[16]  M. Nguyen,et al.  Estrogen induces lung metastasis through a host compartment-specific response. , 2006, Cancer research.

[17]  A. Wolffe,et al.  Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. , 1999, Journal of molecular endocrinology.

[18]  S. K. Shore,et al.  SRC in human carcinogenesis. , 2003, Frontiers in bioscience : a journal and virtual library.

[19]  Rameen Beroukhim,et al.  Molecular characterization of the tumor microenvironment in breast cancer. , 2004, Cancer cell.

[20]  C. Deng,et al.  The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Planas-Silva,et al.  Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[22]  D. Crowe,et al.  Steroid receptor coactivator 1 deficiency increases MMTV-neu mediated tumor latency and differentiation specific gene expression, decreases metastasis, and inhibits response to PPAR ligands , 2010, BMC Cancer.

[23]  K. Horwitz,et al.  Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. , 2006, Cancer research.

[24]  Ji-ping Wang,et al.  Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible? , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[25]  P. Trojer,et al.  A novel arginine methyltransferase inhibitor with cellular activity. , 2007, Bioorganic & medicinal chemistry letters.

[26]  J. Matthews,et al.  A new class of estrogen receptor beta-selective activators. , 2010, Molecular Interventions.

[27]  G. Hortobagyi,et al.  Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. , 2004, Cancer cell.

[28]  G. Gallick,et al.  Treatment for Advanced Tumors: Src Reclaims Center Stage , 2006, Clinical Cancer Research.

[29]  Tinghuai Wang,et al.  17β-Estradiol Enhances Breast Cancer Cell Motility and Invasion via Extra-Nuclear Activation of Actin-Binding Protein Ezrin , 2011, PloS one.

[30]  Chiang-Ching Huang,et al.  Identification of estrogen-responsive genes involved in breast cancer metastases to the bone , 2007, Clinical & Experimental Metastasis.

[31]  Jiong Wu,et al.  Clinical significance of aromatase protein expression in axillary node negative breast cancer , 2007, Journal of Cancer Research and Clinical Oncology.

[32]  Maria Sjöberg,et al.  Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. , 2005, Molecular endocrinology.

[33]  Adrian V. Lee,et al.  Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. , 2003, Cancer research.

[34]  P. Chambon,et al.  Functional domains of the human estrogen receptor , 1987, Cell.

[35]  Y. Yamaguchi.  Microenvironmental regulation of estrogen signals in breast cancer , 2007, Breast cancer.

[36]  L. Stephens,et al.  Metastasis Tumor Antigen Family Proteins during Breast Cancer Progression and Metastasis in a Reliable Mouse Model for Human Breast Cancer , 2006, Clinical Cancer Research.

[37]  D. McDonnell,et al.  Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. , 2005, Molecular interventions.

[38]  Myles A Brown,et al.  Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland. , 2006, Cancer research.

[39]  B. O’Malley,et al.  Steroid receptor coactivator (SRC)-1 and SRC-3 differentially modulate tissue-specific activation functions of the progesterone receptor. , 2006, Molecular endocrinology.

[40]  Carlos S. Moreno,et al.  MTA3, a Mi-2/NuRD Complex Subunit, Regulates an Invasive Growth Pathway in Breast Cancer , 2003, Cell.

[41]  P. Steeg.  Tumor metastasis: mechanistic insights and clinical challenges , 2006, Nature Medicine.

[42]  J. Depasquale.  Rearrangement of the F-actin cytoskeleton in estradiol-treated MCF-7 breast carcinoma cells , 1999, Histochemistry and Cell Biology.

[43]  E. Levin,et al.  Integration of the extranuclear and nuclear actions of estrogen. , 2005, Molecular endocrinology.

[44]  Fei Huang,et al.  Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. , 2007, Cancer research.

[45]  M. Dowsett,et al.  Combination therapy with aromatase inhibitors: the next era of breast cancer treatment? , 2006, British Journal of Cancer.

[46]  B. O’Malley,et al.  Nuclear receptor coregulators in cancer biology. , 2009, Cancer research.

[47]  Anupama E. Gururaj,et al.  The Clinical Relevance of Steroid Hormone Receptor Corepressors , 2005, Clinical Cancer Research.

[48]  V. Speirs,et al.  Oestrogen receptor β: what it means for patients with breast cancer , 2004 .

[49]  Donald P. McDonnell,et al.  Connections and Regulation of the Human Estrogen Receptor , 2002, Science.

[50]  V. Speirs,et al.  Reduced expression of oestrogen receptor β in invasive breast cancer and its re‐expression using DNA methyl transferase inhibitors in a cell line model , 2003, The Journal of pathology.

[51]  Christopher Logothetis,et al.  Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. , 2010, Cancer treatment reviews.

[52]  R. Tekmal,et al.  Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy , 2011, Steroids.

[53]  N. Levy,et al.  Liquiritigenin is a plant-derived highly selective estrogen receptor β agonist , 2008, Molecular and Cellular Endocrinology.

[54]  I. Leav,et al.  ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. , 2010, Cancer cell.

[55]  Luzhe Sun,et al.  Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells. , 2010, Cancer research.

[56]  L. Beex,et al.  Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis , 1991, Breast Cancer Research and Treatment.

[57]  L. Corbo,et al.  Protein arginine methylation in estrogen signaling and estrogen-related cancers , 2010, Trends in Endocrinology & Metabolism.

[58]  E. Lander,et al.  Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. , 2008, Cancer research.

[59]  G. Ball,et al.  The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype , 2010, Breast Cancer Research and Treatment.

[60]  P. Friedl,et al.  Tumour-cell invasion and migration: diversity and escape mechanisms , 2003, Nature Reviews Cancer.

[61]  Sandip K. Mishra,et al.  Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor , 2000, Nature Cell Biology.

[62]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[63]  B. O’Malley,et al.  Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. , 1998, Science.

[64]  S. Dedhar,et al.  The role of integrin-linked kinase (ILK) in cancer progression , 2003, Cancer and Metastasis Reviews.

[65]  I. Beavon.  The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. , 2000, European journal of cancer.

[66]  M. Nieto,et al.  The ins and outs of the epithelial to mesenchymal transition in health and disease. , 2011, Annual review of cell and developmental biology.

[67]  S. Nair,et al.  Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor. , 2007, Cancer research.

[68]  C. J. Barnes,et al.  A naturally occurring MTA1 variant sequesters oestrogen receptor-α in the cytoplasm , 2002, Nature.

[69]  B. O’Malley.  Little Molecules with Big Goals , 2006, Science.

[70]  S. Davis,et al.  Minireview: Aromatase and the Regulation of Estrogen Biosynthesis-Some New Perspectives. , 2001, Endocrinology.

[71]  Jian-ming Zheng,et al.  Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression☆ ☆ This study was supported by the National Natural Science Foundation of China (No. 39870753) and Changhai Hospital ‘123’ Project. , 2001, Steroids.

[72]  J. Gustafsson,et al.  Estrogen Receptors: Therapies Targeted to Receptor Subtypes , 2011, Clinical pharmacology and therapeutics.

[73]  B. O’Malley,et al.  Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.

[74]  S. Nair,et al.  Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells. , 2008, Molecular endocrinology.

[75]  Simone Brabletz,et al.  E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer , 2009, Cancer and Metastasis Reviews.

[76]  Andrea Riccardo Genazzani,et al.  Estrogen Receptor- (cid:1) Promotes Breast Cancer Cell Motility and Invasion via Focal Adhesion Kinase and N-WASP , 2010 .

[77]  R. Finn,et al.  Targeting Src in breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[78]  J. Hartman,et al.  Estrogen receptor β inhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D , 2004 .

[79]  H. Muss.  Targeted therapy for metastatic breast cancer. , 2006, The New England journal of medicine.

[80]  J. Gustafsson,et al.  Expression of estrogen receptor β increases integrin α1 and integrin β1 levels and enhances adhesion of breast cancer cells , 2010, Journal of cellular physiology.

[81]  Sung-Won Kim,et al.  Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression. , 2007, Oncology reports.

[82]  K. Gelmon,et al.  QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model , 2009, Breast Cancer Research.

[83]  J. Gustafsson,et al.  The different roles of ER subtypes in cancer biology and therapy , 2011, Nature Reviews Cancer.

[84]  P. Elvin,et al.  Src inhibitors in early breast cancer: a methodology, feasibility and variability study , 2009, Breast Cancer Research and Treatment.

[85]  B. O’Malley,et al.  The AIB1 Oncogene Promotes Breast Cancer Metastasis by Activation of PEA3-Mediated Matrix Metalloproteinase 2 (MMP2) and MMP9 Expression , 2008, Molecular and Cellular Biology.

[86]  Ji-ping Wang,et al.  Estrogen stimulation of cell migration involves multiple signaling pathway interactions. , 2010, Endocrinology.

[87]  S. Barsky,et al.  ERα suppresses slug expression directly by transcriptional repression , 2008, The Biochemical journal.

[88]  L. Liotta,et al.  Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.